Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all- cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Apogee is also developing APG273, a combination therapy consisting of zumilokibart and APG333, an anti- TSLP antibody, for asthma. Phase 1 data indicated APG333 maintained suppression of type 2 inflammatory markers for up to s ...